HighRad Ltd.
HighRAD offers an FDA-cleared oncology AI imaging platform designed to revolutionize cancer care by providing longitudinal, multi-organ analysis for a deeper understanding of disease progression. Their solutions, including iCAS-LV, iCAS-LG, and iCAS-BR, leverage AI for automated, quantitative measurement of lesions across various organs, significantly speeding up assessments and improving reporting times. The platform enhances treatment planning support, improves clinical outcomes, and facilitates data integration compliant with RECIST 1.1 guidelines, also serving as a valuable tool for pharmaceutical companies in evaluating treatment responses and clinical studies.
HighRad Ltd.
HighRAD offers an FDA-cleared oncology AI imaging platform designed to revolutionize cancer care by providing longitudinal, multi-organ analysis for a deeper understanding of disease progression. Their solutions, including iCAS-LV, iCAS-LG, and iCAS-BR, leverage AI for automated, quantitative measurement of lesions across various organs, significantly speeding up assessments and improving reporting times. The platform enhances treatment planning support, improves clinical outcomes, and facilitates data integration compliant with RECIST 1.1 guidelines, also serving as a valuable tool for pharmaceutical companies in evaluating treatment responses and clinical studies.